This article was originally published in The Gray Sheet
Ophthalmic laser manufacturer plans secondary offering of 1 mil. shares of common stock. The Waltham, Massachusetts-based firm says a registration statement for the offering has been filed with the Securities and Exchange Commission. Proceeds will be used for: "expansion of manufacturing, selling, marketing, service and administrative capabilities"; R&D and regulatory costs; "funding and development of a network of outpatient clinics"; and "potential acquisition of certain intellectual property rights." Summit stock currently is trading in the $23 range. Bear Stearns and Piper Jaffray are underwriting the offering.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.